Statin therapy has gained interest in the field of hypertension due to the potential role of different statin agents in blood pressure (BP) lowering [1] [2] [3] . The potential mechanisms involved include the downregulation of the angiotensin II-type 1 receptor, the decrease of vasoconstrictor endothelin-1 levels, and the increase in the endothelial production of nitric oxide (NO), an effect that is correlated with the upregulation of endothelial NO synthase expression [4] [5] [6] . Furthermore, we have recently reported the effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with hypertension and normal cholesterol levels [7] . Yet, despite the beneficial effects shown by statins in hypertensive animal models as well as in small clinical studies, the results from meta-analyses and large clinical trials have been controversial.
Manfredi Rizzo, Giuseppe Montalto, Maciej Banach small, dense LDL. The pathophysiology, atherogenicity and clinical significance of these LDL particles have already been highlighted in the recent consensus statement of a European panel of experts [14, 15] .
Owczarek et al. in the present issue of Archives of Medical Science [16] report no beneficial effects of simvastatin after 4 weeks of therapy on BP and heart rate after metoprolol injection in animal models (rats). The authors have already observed similar effects in two other studies with a 2-week period of statin administration [17, 18] . Yet, a reduction in heart rate and BP has been reported in patients with hypertension and type-2 diabetes with the concomitant administration of simvastatin and metoprolol [19] , and other studies evaluated the effects of such combined therapy on C-reactive protein levels [20] . We cannot exclude that therapeutic modulation of enhanced inflammation and/or atherogenic dyslipidaemia may contribute to the beneficial effect shown by simvastatin on blood pressure, especially considering that the study by Owczarek et al. has some important limitations connected to the length of the intervention (only 4 weeks), the dose and the type of statin, and finally with the selection of hypertension drug: metoprolol, an old β 1 receptor blocker without a nitric oxide-potentiating vasodilatory effect [16, 21] .
In conclusion, as recently highlighted, there is more to predicting vascular disease than just established risk factors [22] . Patients with hypertension benefit from statin administration, independently of their plasma lipid levels, and independently of the influence on their BP. Inflammation and atherogenic dyslipidaemia may play a role [23] [24] [25] . Future well-designed clinical trials with carefully selected endpoints are needed in order to demonstrate whether statins definitely have an anti-hypertensive effect. Such studies should also investigate the synergistic effects of hypertension and atherogenic lipoproteins on CV risk.
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